Author(s): Sangita P. Shirsat, Kaveri P. Tambe, Ganesh G. Dhakad, Paresh A. Patil


DOI: 10.52711/0975-4377.2022.00005   

Address: Sangita P. Shirsat, Kaveri P. Tambe, Ganesh G. Dhakad, Paresh A. Patil*
Ahinas Institute of Pharmacy, Dondaicha 425408.
*Corresponding Author

Published In:   Volume - 14,      Issue - 1,     Year - 2022

The four main classes of antifungal drugs are the polyenes, Azoles, allylamines and echinocandins. Clinically useful “older” agents include topical azole Formulations (for superficial yeast and dermatophyte Infections), first-generation triazoles (fluconazole and Itraconazole, for a range of superficial and invasive fungal Infections), amphotericin B formulations (for a broad range of Invasive fungal infections) and terbinafine (for dermatophyte Infections). Clinically important “newer” agents include members of the Echinocandin class (eg, caspofungin) and second-generation Triazoles (eg, voriconazole and posaconazole). Voriconazole and posaconazole have broad-spectrum activity Against yeasts and moulds, including Aspergillus species. Posaconazole is the only azole drug with activity against Zygomycete fungi. Caspofungin and the other echinocandins are effective in Treating Candida and Aspergillus infections. The azoles are relatively safe, but clinicians should be aware Of drug–drug interactions and adverse effects, including Visual disturbances (with voriconazole), elevations in liver Transaminase levels, and skin rashes. Caspofungin has Minimal adverse effects. Combination antifungal therapy may be appropriate in Selected patients with invasive fungal infections, but is Empiric and driven by individual physician practice. Clinical needs for novel antifungal agents have altered.

Cite this article:
Sangita P. Shirsat, Kaveri P. Tambe, Ganesh G. Dhakad, Paresh A. Patil. Review on Antifungal Agents. Research Journal of Pharmaceutical Dosage Forms and Technology.2022; 14(1):29-2. doi: 10.52711/0975-4377.2022.00005

Sangita P. Shirsat, Kaveri P. Tambe, Ganesh G. Dhakad, Paresh A. Patil. Review on Antifungal Agents. Research Journal of Pharmaceutical Dosage Forms and Technology.2022; 14(1):29-2. doi: 10.52711/0975-4377.2022.00005   Available on:

1.    Develoux, M. (2001) Griseofulvin. Ann. Dermatol. Venere´ol. 128,1317–1325
2.    Woyke, T. Et al. (2002) Effect of auristatin PHE on microtubuleIntegrity and nuclear localization in Cryptococcus neoformans. AntimicrobAntimicrob. Agents Chemother. 46, 3802–3808
3.    Pfaller, M.A. et al. (2002) In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary Resistance using national committee for clinical laboratory standards Susceptibility testing methods. Antimicrob. Agents Chemother. 46,3518–3521
4.    Brajtburg, J.K. et al. (1974) The molecular basis for the selective Toxicity of amphotericin B for yeast and filipin for animal oils. Antimicrob. Agents Chemother. 5, 377–382
5.    Dupont, B. (2002) Overview of the lipid formulations of amphotericin B. J. Antimicrob. Chemother. 49, 31–36
6.    Zarif, L. Et al. (2000) Cochleates: new lipid-based drug delivery system. JJ. Liposome Res. 10, 523–538
7.    Falk, R. Et al. (1999) A novel injectable water-soluble amphotericin B-arabinogalactan conjugate. Antimicrob. Agents Chemother. 43,1975–1981
8.    Anonymous (2001) Liposomal nystatin – Nyotranw Antifungal. Drugs Future 26, 810
9.    Vanden Bossche, H. Et al. (1995) P450 inhibitors of use in medical Treatment: focus on mechanisms of action. Pharmacol. Ther. 67,79–100
10.    Kauffman CA. New antifungal agents. Semin Respir Crit Care Med 2004;25: 233-239.
11.    Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azoleAntifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
12.    Walsh TJ, Groll A, Hiemenez J, et al. Infections due to emerging and Uncommon medically important fungal pathogens. Clin Microbial Infect2004; 10 Suppl 1: 48-66.
13.    Pfaller MA, Diekma DJ. Rare and emerging opportunistic fungal patho-Gens: concern for resistance beyond Candida albicans and AspergillusFumigatus. J Clin Microbiol 2004; 42: 4419-4431.
14.    Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of blood streamInfection due to Candida species and in vitro susceptibilities of isolatesCollected from 1998 to 2000 in a population-based active surveillance Program. J Clin Microbiol 2004; 42: 1519-1527.
15.    Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould Infections in haematopoietic stem cell transplant recipients. Clin InfectDis 2002; 34: 909-917.
16.    Lin S, Schranz J, Teutsch S. Aspergillosis case-fatality rate: systemicReview of the literature. Clin Infect Dis 2001; 32: 358-366.
17.    Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality ofCandidaemia, revisited. Clin Infect Dis 2003; 37: 1172-1177.
18.    Ullmann AJ, Cornerly OA. Antifungal prophylaxis for invasive mycoses inHigh risk patients. Curr Opin Infect Dis 2006; 19: 571-576.
19.    Bow EJ, Laverdière M, Lussier N, et al. Antifungal prophylaxis for severely Neutropenic chemotherapy recipients. A meta-analysis of randomized-Controlled clinical trials. Cancer 2002; 94: 3230-3246.
20.    Cornerly OA, Ullmann AJ, Karthaus M. Evidence-based assessment of Primary antifungal prophylaxis in patients with hematological malignan-Cies. Blood 2003; 101: 3365-3372.
21.    Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic Targets and immunologic strategies. Antimicrob Agents Chemother 1996; 40: 279-291.
22.    Boucher HW, Groll AH, Chiou C, Walsh TJ. Newer systemic antifungal Agents. Drugs 2004; 64: 1997-2020.
23.    Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-Spectrum triazole antifungal. Lancet Infect Dis 2005; 5: 775-785.
24.    Marr KA, Hachem R, Papanicolaou G, et al. Retrospective study of The hepatic safety profile of patients concomitantly treated with cas Pofungin and cyclosporin A. Transpl Infect Dis
25.    Wang E-J, Lew K, Casciano CN, Clement RP, Johnson WW. Inter-
26.    Action of common azole antifungals with P glycoprotein. Antimicrob
27.    macrodilution susceptibility test results for non-AIDS patients wWingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta
28.    A randomized, double-blind comparative trial evaluating the safety Of liposomal amphotericin B versus amphotericin B lipid complex in The empirical treatment of febrile neutropenia. L Amph/ABLC Col-Laborative Study Group. Clin Infect Dis 2000; 31:1155–63.
29.    Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Klei- Nermans D. Pharmacokinetics and safety of voriconazole following Intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46:2546–53.

Recomonded Articles:

Author(s): Varsha R. Sandhan, S.B. Gondkar, R. B. Saudagar

DOI:         Access: Open Access Read More

Author(s): Samadhan K. Deore, Rajendra K Surawase, Avish Maru

DOI: 10.5958/0975-4377.2019.00045.4         Access: Open Access Read More

Author(s): Tushar D. Sonawane, Rajesh Z. Mujoriya

DOI: 10.5958/0975-4377.2016.00023.9         Access: Open Access Read More

Author(s): Juned Khan, Ajazuddin, SJ Daharwal, Deependra Singh

DOI:         Access: Open Access Read More

Author(s): Mohan Krishna Lokireddy, Jayachandra Reddy P, M. Srinivasa Murthy

DOI:         Access: Open Access Read More

Author(s): Sangita P. Shirsat, Kaveri P. Tambe, Ganesh G. Dhakad, Paresh A. Patil

DOI: 10.52711/0975-4377.2022.00005         Access: Closed Access Read More

Research Journal of Pharmaceutical Dosage Forms and Technology (RJPDFT) is an international, peer-reviewed journal, devoted to pharmaceutical sciences. ...... Read more >>>

RNI: Not Available                     
DOI: 10.5958/0975-4377 

Recent Articles